The standard treatments for overactive bladder include lifestyle changes, bladder training, pelvic floor muscle training and anticholinergic (anti-muscarinic) drugs. Additional treatments for some ...
Sumitomo Pharma's Gemtesa (vibegron) has been approved by the U.S. Food and Drug Administration for men with overactive ...
The FDA has approved Gemtesa® for men with overactive bladder symptoms receiving pharmacological therapy for BPH.
HealthDay on MSN5d
FDA Approves Gemtesa for Overactive Bladder in Men With BPHGemtesa (vibegron) has been approved by the U.S. Food and Drug Administration for men with overactive bladder (OAB) s ...
An overactive bladder may be temporary or become a chronic condition. How long the symptoms last may depend on factors like the underlying cause and treatment adherence. Some conditions may cause ...
Imbrium Therapeutics L.P. ("Imbrium"), a subsidiary of Purdue Pharma L.P. ("Purdue"), announced results from a Phase 1b clinical signal detection study evaluating the safety and efficacy of the novel ...
The platform is designed to highlight the impact of OAB symptoms and educate on disease management, including information on treatment options, such as GEMTESA® (vibegron). In this exclusive with ...
Treatment with vibegron reduced the average number of micturition episodes per day and the average number of daily urgency episodes compared with placebo. The Food and Drug Administration (FDA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback